This phase III trial studies whether the addition of definitive treatment (radiation or surgical removal) of the primary tumor to standard systemic therapy for patients with prostate cancer, may help prevent the cancer from the spreading to other parts of their body. Removing the prostate by either surgery or radiation therapy in addition to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading. Eligibility includes being at least 18 years old and:
All patients must have a histologically or cytologically proven diagnosis of adenocarcinoma of the prostate.
Patients must have an intact prostate.
Must have metastatic disease
